ADA: Bisphenol A Linked to Reduced Peripheral Insulin Sensitivity
By Elana Gotkine HealthDay Reporter
THURSDAY, June 27, 2024 -- Bisphenol A (BPA) administration is associated with reduced peripheral insulin sensitivity among healthy adults, according to a study presented at the annual meeting of the American Diabetes Association, held from June 21 to 24 in Orlando, Florida.
Adam Seal, Ph.D., from the California Polytechnic State University in San Luis Obispo, and colleagues examined the effects of oral BPA administration on peripheral insulin sensitivity in 40 nonhabitually active, healthy adults. Participants completed a two-day baseline energy balance diet low in bisphenols and were then randomly assigned to a four-day energy balance diet plus oral BPA administration at 50 µg/kg body weight (BPA-50) or four-day energy balance diet plus oral placebo (PL) administration.
The researchers found that body weight was not significantly different between the PL and BPA-50 groups from baseline to four days. Fasting blood glucose did not differ significantly between the groups from baseline to four days. Urine BPA was significantly higher following BPA-50 than PL. Peripheral insulin sensitivity decreased significantly with BPA-50 and remained stable in PL from baseline to four days.
"Given that diabetes is a leading cause of death in the United States, it is crucial to understand even the smallest factors that contribute to the disease," coauthor Todd Hagobian, Ph.D., also from the California Polytechnic State University, said in a statement.
One author disclosed ties to Weight Watchers International.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia
THURSDAY, April 24, 2025 -- Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.